431 related articles for article (PubMed ID: 3937277)
1. Clinical application of a chromogenic substrate method for determination of factor VIII activity.
Rosén S; Andersson M; Blombäck M; Hägglund U; Larrieu MJ; Wolf M; Boyer C; Rothschild C; Nilsson IM; Sjörin E
Thromb Haemost; 1985 Dec; 54(4):818-23. PubMed ID: 3937277
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of the chromogenic assay of factor VIII in haemophilia A, and different variants of von Willebrand's disease.
Lethagen S; Ostergaard H; Nilsson IM
Scand J Haematol; 1986 Nov; 37(5):448-53. PubMed ID: 3101169
[TBL] [Abstract][Full Text] [Related]
3. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
Mazurier C; Parquet-Gernez A; Goudemand M
Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
[TBL] [Abstract][Full Text] [Related]
4. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
5. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
6. DDAVP (desmopressin) in the dental management of patients with mild or moderate hemophilia and von Willebrand's disease.
Vierrou AM; de la Fuente B; Poole AE; Hoyer LW
Pediatr Dent; 1985 Dec; 7(4):297-301. PubMed ID: 2938080
[No Abstract] [Full Text] [Related]
7. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in hemophilia.
Tann G
Southeast Asian J Trop Med Public Health; 1979 Jun; 10(2):218-28. PubMed ID: 524146
[TBL] [Abstract][Full Text] [Related]
9. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
Lundblad RL; Kingdon HS; Mann KG; White GC
Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
[TBL] [Abstract][Full Text] [Related]
10. [Determination of clotting factor VIII activity in mammals using the one-stage clotting and the chromogenic methods].
Lutze G; Lutze G; Kutschmann K; Schröpel M
Berl Munch Tierarztl Wochenschr; 2002; 115(7-8):297-302. PubMed ID: 12174728
[TBL] [Abstract][Full Text] [Related]
11. Progress and problems in hemophilia and von Willebrand's disease.
Abildgaard CF
Adv Pediatr; 1984; 31():137-77. PubMed ID: 6440429
[No Abstract] [Full Text] [Related]
12. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
13. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
[TBL] [Abstract][Full Text] [Related]
14. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion.
Casonato A; Pontara E; Boscaro M; Dannhauser D; Sartori MT; Girolami A
Haematologia (Budap); 1993; 25(1):57-67. PubMed ID: 8339998
[TBL] [Abstract][Full Text] [Related]
15. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
[TBL] [Abstract][Full Text] [Related]
16. [Multimeric composition of factor VIII-related protein following DDAVP infusion in normal subjects and patients with hemophilia A and von Willebrand's disease].
Takase T; Nishino M; Yasui M; Shima M; Yoshikawa N; Fukui H
Nihon Ketsueki Gakkai Zasshi; 1985 Nov; 48(7):1571-8. PubMed ID: 3937410
[No Abstract] [Full Text] [Related]
17. [Hemostatic effect of deamino-8-D-arginine vasopressin (DDAVP) in hemophilia A and von Willebrand's disease].
Fukui H; Takase T
Rinsho Ketsueki; 1985 Jul; 26(7):1069-79. PubMed ID: 3932720
[No Abstract] [Full Text] [Related]
18. Open-heart surgery in von Willebrand's disease.
Aris A; Pisciotta AV; Hussey CV; Gale H; Lepley D
J Thorac Cardiovasc Surg; 1975 Feb; 69(2):183-7. PubMed ID: 1078707
[TBL] [Abstract][Full Text] [Related]
19. Hemophilia and von Willebrand's disease: genetic considerations.
Green D
Ann Clin Lab Sci; 1980; 10(2):123-7. PubMed ID: 6770741
[TBL] [Abstract][Full Text] [Related]
20. 1-Deamino-8-D-arginine-vasopressin--an alternative in the management of mild haemophilia A and von Willebrand's disease.
Niessner H; Korninger C
Wien Klin Wochenschr; 1983 Nov; 95(21):753-7. PubMed ID: 6424339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
